Skip to main content

Hims & Hers Health, Inc. (HIMS) Stock Analysis

Falling Knife setup

SellModerate Confidence

Healthcare · Drug Manufacturers - Specialty & Generic

Sell if holding. Engine safety override at $22.58: Quality below floor (3.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.3/10. Specifically: High short interest: 33%; Elevated put/call ratio: 1.61; Below-average business quality.

Hims & Hers is a US-led telehealth and digital health platform offering subscription-based prescription and non-prescription treatments for sexual health, hair loss, weight loss, dermatology, and mental health. Revenue grew from $872M (2023) to $2,347.6M (2025), driven primarily... Read more

$22.58+2.6% A.UpsideScore 4.3/10#28 of 29 Drug Manufacturers - Specialty & Generic
QualityF-score8 / 9FCF yield3.36%
Stop $20.88Target $23.02(analyst − 13%)A.R:R 0.2:1
Analyst target$26.46+17.2%14 analysts
$23.02our TP
$22.58price
$26.46mean
$18
$35

Sell if holding. Engine safety override at $22.58: Quality below floor (3.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.3/10. Specifically: High short interest: 33%; Elevated put/call ratio: 1.61; Below-average business quality. Chart setup: Death cross, below all MAs, RSI 38, MACD bearish. Score 4.3/10, moderate confidence.

Passes 5/8 gates (clean insider activity, no SEC red flags, earnings proximity 82d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and death cross (50MA < 200MA). Suitability: aggressive.

Val6.8Qual3.8Grw3.5Mom3.6Sent5.7Ins3.4Peer2.9Tech6.2Risk2.54.3OVERALL

Recent Developments — Hims & Hers Health, Inc.

Latest news

Generated 2026-05-20T21:06:21Z.

Thesis

Rewards
No bull case signals
Risks
Target reached (2.6% upside)
Quality below floor (3.8 < 4.0)

Key Metrics

P/E (TTM)—
P/E (Fwd)17.4
Mkt Cap$5.2B
EV/EBITDA66.8
Profit Mgn-0.6%
ROE-2.7%
Rev Growth3.8%
Beta2.42
DividendNone
Rating analysts23

Quality Signals

Piotroski F8/9

Options Flow

P/C1.61bearish
IV85%elevated
Max Pain$10-55.7% vs spot

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

5 floor-breakers

Volatile — 8.8% daily ATR makes tight stops impractical. Position-size conservatively.static

Volatility
0.0
Implied Vol
0.0
Short Interest
0.2
Beta
1.9
Debt Equity
2.5
Put Call
2.6
Max Pain Risk
3.0
News Risk
3.0
Days To Cover
9.0
High short interest justified: 33%Elevated put/call: 1.61High IV: 85%Above max pain $10

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Quality Rank
2.5
Growth Rank
4.1
Value Rank
5.0

Growth below the gate floor. Component breakdown shows what dragged the score down.static

Revenue Growth
3.5
Low model confidence on this dimension (33%).

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Macd
0.0
Ma Position
1.0
Volume
3.3
Rsi
3.5
Obv
10.0
Volume accumulation (rising OBV)Below 200-MA, MA slope -10.0%/30d — confirmed downtrend

Unprofitable operations — net margin -0.6%. Quality floor flags this regardless of sector context.static

Roe
0.0
Operating Margin
0.0
Net Margin
0.0
Roa
0.4
Rule Of 40
3.0
Moat
4.6
Fcf Quality
5.0
Current Ratio
6.1
Piotroski F
8.9
Gross Margin
10.0
FCF-positive despite GAAP loss (FCF margin 7%, FCF yield 3.4%)No competitive moatRule of 40: 11 (fail)Strong Piotroski F-Score: 8/9
GatesMomentum 3.6<4.5A.R:R 0.2 < 1.5@spotDeath cross (50MA < 200MA)Insider activity: OKNo SEC red flagsEARNINGS PROXIMITY 82d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARFalling KnifeSuitability: Aggressive
RSI
38 · Neutral
↓ 20D MA↓ 50D MA↓ 200D MADEATH CROSSSupport $21.53Resistance $31.44

Price Targets

$21
$23
A.Upside+1.9%
A.R:R0.2:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Target reached (2.6% upside)
! Quality below floor (3.8 < 4.0)
! Momentum score 3.6/10 — below 4.5 minimum

Earnings

B
B
M
M
2/4 beats
Next Earnings2026-08-10 (82d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is HIMS stock a buy right now?

Sell if holding. Engine safety override at $22.58: Quality below floor (3.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.3/10. Specifically: High short interest: 33%; Elevated put/call ratio: 1.61; Below-average business quality. Chart setup: Death cross, below all MAs, RSI 38, MACD bearish. Prior stop was $20.88. Score 4.3/10, moderate confidence.

What is the HIMS stock price target?

Take-profit target: $23.02 (+2.6% upside). Prior stop was $20.88. Stop-loss: $20.88.

What are the risks of investing in HIMS?

Target reached (2.6% upside); Quality below floor (3.8 < 4.0).

Is HIMS overvalued or undervalued?

Hims & Hers Health, Inc. trades at a P/E of N/A (forward 17.4). TrendMatrix value score: 6.8/10. Verdict: Sell.

What do analysts say about HIMS?

23 analysts cover HIMS with a consensus score of 3.5/5. Average price target: $26.

What does Hims & Hers Health, Inc. do?Hims & Hers is a US-led telehealth and digital health platform offering subscription-based prescription and...

Hims & Hers is a US-led telehealth and digital health platform offering subscription-based prescription and non-prescription treatments for sexual health, hair loss, weight loss, dermatology, and mental health. Revenue grew from $872M (2023) to $2,347.6M (2025), driven primarily by US subscription-based prescription products fulfilled through company-owned pharmacies and partner pharmacies. The company faces regulatory risk around GLP-1 compounded semaglutide.

Related stocks: NBIX (Neurocrine Biosciences, Inc.) · INDV (Indivior Pharmaceuticals, Inc.) · ANIP (ANI Pharmaceuticals, Inc.) · COLL (Collegium Pharmaceutical, Inc.) · BHC (Bausch Health Companies Inc.)